Logo image of CNTG

CENTOGENE NV (CNTG) Stock Price, Forecast & Analysis

USA - NASDAQ:CNTG - NL0014040206 - Common Stock

0.325 USD
-0.02 (-6.23%)
Last: 8/7/2024, 8:06:53 PM
0.351 USD
+0.03 (+8%)
After Hours: 8/7/2024, 8:06:53 PM

CNTG Key Statistics, Chart & Performance

Key Statistics
Market Cap8.97M
Revenue(TTM)48.54M
Net Income(TTM)-35.53M
Shares27.60M
Float18.60M
52 Week High1.53
52 Week Low0.25
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.39
PEN/A
Fwd PEN/A
Earnings (Next)09-04 2024-09-04
IPO2019-11-07
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Providers & Services
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Services


CNTG short term performance overview.The bars show the price performance of CNTG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

CNTG long term performance overview.The bars show the price performance of CNTG in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CNTG is 0.325 USD. In the past month the price decreased by -33.52%. In the past year, price decreased by -68.45%.

CENTOGENE NV / CNTG Daily stock chart

CNTG Latest News, Press Relases and Analysis

CNTG Competitors/Peers

The largest stocks on the US markets in the "Health Care Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
CVS CVS HEALTH CORP11.53100.19B
CI THE CIGNA GROUP9.3170.62B
LH LABCORP HOLDINGS INC15.9721.00B
DGX QUEST DIAGNOSTICS INC18.3920.07B
BTSGU BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27110.3219.93B
GH GUARDANT HEALTH INCN/A12.06B
HIMS HIMS & HERS HEALTH INC75.989.27B
DVA DAVITA INC13.48.84B
CHE CHEMED CORP19.766.33B
RDNT RADNET INC217.536.02B
BTSG BRIGHTSPRING HEALTH SERVICES32.495.87B
OPCH OPTION CARE HEALTH INC18.564.49B

About CNTG

Company Profile

CNTG logo image Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.

Company Info

CENTOGENE NV

Am Strande 7

Rostock MECKLENBURG-VORPOMMERN 18055 DE

CEO: Andrin Oswald

Employees: 493

CNTG Company Website

Phone: 4938180113400

CENTOGENE NV / CNTG FAQ

Can you describe the business of CENTOGENE NV?

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.


What is the current price of CNTG stock?

The current stock price of CNTG is 0.325 USD. The price decreased by -6.23% in the last trading session.


Does CNTG stock pay dividends?

CNTG does not pay a dividend.


What is the ChartMill rating of CENTOGENE NV stock?

CNTG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the analyst forecast for CNTG stock?

7 analysts have analysed CNTG and the average price target is 1.53 USD. This implies a price increase of 370.77% is expected in the next year compared to the current price of 0.325.


Can you provide the sector and industry classification for CENTOGENE NV?

CENTOGENE NV (CNTG) operates in the Health Care sector and the Health Care Providers & Services industry.


CNTG Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CNTG Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CNTG. CNTG has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CNTG Financial Highlights

Over the last trailing twelve months CNTG reported a non-GAAP Earnings per Share(EPS) of -1.39. The EPS decreased by -6.92% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -46.05%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-6.92%
Sales Q2Q%254.74%
EPS 1Y (TTM)-6.92%
Revenue 1Y (TTM)2.25%

CNTG Forecast & Estimates

7 analysts have analysed CNTG and the average price target is 1.53 USD. This implies a price increase of 370.77% is expected in the next year compared to the current price of 0.325.

For the next year, analysts expect an EPS growth of 39.38% and a revenue growth 22.37% for CNTG


Analysts
Analysts82.86
Price Target1.53 (370.77%)
EPS Next Y39.38%
Revenue Next Year22.37%

CNTG Ownership

Ownership
Inst Owners0.09%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A